When available, the Online Course format is included with the hard copy, eBook, or audio book formats!
Release Date: July 27, 2016
Expiration Date: July 31, 2019
Diabetes is a chronic disease state with no known cure. For this reason, diabetes management is intended to prevent complications and improve the patient’s quality of life. If diabetes is left untreated or is poorly managed, the patient’s disease may progress more rapidly or precipitate a hyperglycemic crisis, or the patient may experience treatment-related adverse events, such as hypoglycemia.
As a result of its high prevalence and economic burden, diabetes management is an area of tremendous research. Many new pharmacotherapies have become available in recent years. The variety of options is ideal for patients with diabetes, but this vast array of choices may make treating diabetes daunting for healthcare providers. In addition, new guidelines for the treatment of diabetes are released by the American Diabetes Association yearly and the American Association of Clinical Endocrinologists every other year. In order to effectively manage patients with diabetes, it is important to stay current with the standard of care for treatment of diabetes and the therapeutic options available. Clinicians need to understand that guidelines are meant as a “guide” to be used along with critical thinking and patient-shared decision making. There are multiple diabetes guidelines available for consultation; this course will consider two such guidelines to review current treatment recommendations for diabetes management and the pharmacotherapies, both new and time-tested, currently available.
- Identify appropriate treatment goals to help guide pharmacologic therapy choices for a patient with diabetes.
- Recognize the time-action profiles and usual uses of insulin formulations.
- Compare and contrast the safety and efficacy of pharmacotherapies used in the management of diabetes.
- Identify adverse events that patients may experience while using pharmacotherapy for diabetes management and contraindications to therapy.
Dhiren K. Patel, PharmD, CDE, BC-ADM, BCACP, is an associate professor of pharmacy practice in the School of Pharmacy – Boston at MCPHS University (formerly Massachusetts College of Pharmacy and Health Sciences). He also maintains a clinical practice site with the VA Boston Healthcare System, where he functions as a mid-level provider for a variety of chronic diseases such as diabetes, hypertension, dyslipidemia, and obesity. He earned his PharmD from MCPHS University and received his postdoctoral residency training at the VA Boston Healthcare System. He is also board-certified in advanced diabetes management (BC-ADM), as an ambulatory care pharmacist (BCACP), and as a diabetes educator (CDE). Dr. Patel is one of the co-authors of the Obesity and Diabetes chapters in Koda-Kimble and Young’s Applied Therapeutics: The Clinical Use of Drugs, the first clinical pharmacy textbook to be based on patient case histories. This book is now in its 11th edition, has been translated into many languages, and is widely used in the United States and internationally. Dr. Patel has also been published in numerous peerreviewed journals and has delivered numerous presentations and lectures on obesity.
- Contact hours will be awarded for up to one (1) year from date of purchase or by the expiration date indicated above, whichever date comes first.
- You must score 75% or higher on the final exam and complete the course evaluation to pass this course and receive a certificate of completion.
- Through our review processes, Western Schools ensures that this course content is presented in a balanced, unbiased manner and is free from commercial influence. It is Western Schools’ policy not to accept commercial support.
- All persons involved in the planning and development of this course have disclosed no relevant financial relationships or other conflicts of interest related to the course content.
- Dhiren K. Patel has disclosed that he is on the Speaker’s Bureau for Sanofi, Novo Nordisk, and Merck, and that he is on the Advisory Board for Sanofi, Novo Nordisk, and AstraZeneca. He has agreed to present content that is current, evidence-based, and without bias.